AIM: To investigate the prevalence and genotypic profile of overt and occult hepatitis-B infection (OBI) among HIV-infected individuals in Cameroon. METHODS: 212 HIV-infected Cameroonians, aged 37.6 [IQR: 32.6-46.6] followed-up at the University Health Centre in Yaoundé, were tested for HBsAg, anti-HBs, anti-HBc IgG/IgM, HBV-DNA and anti-HCV IgG. HBV positive cases were tested for Hepatitis Delta virus (HDV) using anti-HDV IgG and HDV-RNA. Liver function was assessed by alanine and aspartate aminotransaminases. OBI was defined as negative-HBsAg and detectable HBV-DNA. In occult or overt HBVinfected participants, HBV reverse transcriptase (RT)/surface (S) sequences were analyzed for drug resistance, immuneescape mutants, and phylogeny. RESULTS: Overall, 78.3% (166/212) participants had past/ongoing HBV-exposure, with 39.1% (83/212) carrying "HBcAbpositive alone". Prevalence of overt HBV (positive-HBsAg) was 11.8% (25/212), prevalence of HBV and HDV was respectively 6.9% (12/175) and 12% (3/25). Phylogeny of HBV-RT/S revealed the co-circulation of genotypes A and E. All HBV-coinfected participants harbored HBV strains with at least one immune-escape mutation. Of note, one HBV variant carried the vaccine-escape mutation G145R that hinders HBsAg neutralization by antibodies. For the first time, a novel 9 aa-deletion (s115-s123), located in the HBsAg "a" determinant, was found concomitantly with OBI. A stop codon in the S region (associated with increased risk of hepatocellular carcinoma) was found in six cases. CONCLUSION: High prevalence of overt/occult HBV-infection and circulating atypical strains highlight the importance of HBV-surveillance among HIV-infected Cameroonians and strategies to detect OBI in highly endemic countries.
AIM: To investigate the prevalence and genotypic profile of overt and occult hepatitis-B infection (OBI) among HIV-infected individuals in Cameroon. METHODS: 212 HIV-infected Cameroonians, aged 37.6 [IQR: 32.6-46.6] followed-up at the University Health Centre in Yaoundé, were tested for HBsAg, anti-HBs, anti-HBc IgG/IgM, HBV-DNA and anti-HCV IgG. HBV positive cases were tested for Hepatitis Delta virus (HDV) using anti-HDV IgG and HDV-RNA. Liver function was assessed by alanine and aspartate aminotransaminases. OBI was defined as negative-HBsAg and detectable HBV-DNA. In occult or overt HBVinfected participants, HBV reverse transcriptase (RT)/surface (S) sequences were analyzed for drug resistance, immuneescape mutants, and phylogeny. RESULTS: Overall, 78.3% (166/212) participants had past/ongoing HBV-exposure, with 39.1% (83/212) carrying "HBcAbpositive alone". Prevalence of overt HBV (positive-HBsAg) was 11.8% (25/212), prevalence of HBV and HDV was respectively 6.9% (12/175) and 12% (3/25). Phylogeny of HBV-RT/S revealed the co-circulation of genotypes A and E. All HBV-coinfected participants harbored HBV strains with at least one immune-escape mutation. Of note, one HBV variant carried the vaccine-escape mutation G145R that hinders HBsAg neutralization by antibodies. For the first time, a novel 9 aa-deletion (s115-s123), located in the HBsAg "a" determinant, was found concomitantly with OBI. A stop codon in the S region (associated with increased risk of hepatocellular carcinoma) was found in six cases. CONCLUSION: High prevalence of overt/occult HBV-infection and circulating atypical strains highlight the importance of HBV-surveillance among HIV-infected Cameroonians and strategies to detect OBI in highly endemic countries.
Authors: Diderot Fopa; Daniel Candotti; Claude T Tagny; Camille Doux; Dora Mbanya; Edward L Murphy; Hany I Kenawy; Farha El Chenawi; Syria Laperche Journal: Blood Transfus Date: 2019-11 Impact factor: 3.443
Authors: Nicholas Petersdorf; Jennifer M Ross; Helen A Weiss; Ruanne V Barnabas; Judith N Wasserheit Journal: J Int AIDS Soc Date: 2016-09-19 Impact factor: 5.396
Authors: Tshifhiwa Magoro; George Gachara; Lufuno Mavhandu; Emmaculate Lum; Helen K Kimbi; Roland N Ndip; Pascal Bessong Journal: Virol J Date: 2016-10-21 Impact factor: 4.099
Authors: Jean Joel Bigna; Marie A Amougou; Serra Lem Asangbeh; Angeladine Malaha Kenne; Steve Raoul N Noumegni; Elodie T Ngo-Malabo; Jean Jacques Noubiap Journal: BMJ Open Date: 2017-06-30 Impact factor: 2.692
Authors: George Gachara; Tshifhiwa Magoro; Lufuno Mavhandu; Emmaculate Lum; Helen K Kimbi; Roland N Ndip; Pascal O Bessong Journal: AIDS Res Ther Date: 2017-03-08 Impact factor: 2.250
Authors: Anne Esther Njom Nlend; Philippe Salomon Nguwoh; Christian Taheu Ngounouh; Hyppolite Kuekou Tchidjou; Constant Anatole Pieme; Jean Mbede Otélé; Véronique Penlap; Vittorio Colizzi; Roger Somo Moyou; Joseph Fokam Journal: PLoS One Date: 2016-09-22 Impact factor: 3.240
Authors: Jean Joel Bigna; Marie A Amougou; Serra Lem Asangbeh; Angeladine Malaha Kenne; Jobert Richie Nansseu Journal: BMJ Open Date: 2017-08-28 Impact factor: 2.692
Authors: Alexander J Stockdale; Mas Chaponda; Apostolos Beloukas; Richard Odame Phillips; Philippa C Matthews; Athanasios Papadimitropoulos; Simon King; Laura Bonnett; Anna Maria Geretti Journal: Lancet Glob Health Date: 2017-10 Impact factor: 26.763